SEC Form 4 · accession 0001123292-17-001204
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cynthia Ann Rask
Director
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $16.90 | Jul 3, 2017 | A | 511 | A | Jul 3, 2017 | Jul 3, 2027 | Common Stock | 511 | 511 | D |
Explanation of responses
- F1This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $5,438.